Core Viewpoint - A significant number of traditional Chinese medicine (TCM) products are expected to exit the market due to new regulations from the National Medical Products Administration, which will require clearer safety information in product instructions by July 1, 2026 [1] Group 1: Regulatory Impact - The new regulation aims to improve the clarity of contraindications, adverse reactions, and precautions in TCM product instructions, addressing the current issue of many entries marked as "unclear" [1] - Experts believe that this regulation will not lead to a mass withdrawal of TCM products but will facilitate the orderly exit of "zombie approvals" that have low clinical value and have not been produced for a long time [1] Group 2: Industry Transformation - The regulation is expected to enhance patient safety through clearer risk warnings, improve quality control of TCM, and promote a shift from quantity expansion to quality prioritization in the industry [1] - This shift will encourage resources to concentrate on companies with high clinical value, strong research foundations, and superior quality systems, fostering a high-quality transformation of the TCM industry [1] Group 3: Recommendations for Pharmaceutical Companies - Pharmaceutical companies are advised to prioritize the review of main products, conduct real-world studies, literature reviews, and necessary toxicology tests, and revise product instructions accordingly [2] - Companies should also establish robust pharmacovigilance systems to ensure drug safety and compliance with regulations, while evaluating and canceling low-value approvals to focus on high-quality products that meet clinical needs [2] Group 4: Understanding TCM - There is a need to recognize the fundamental differences in treatment logic between TCM and Western medicine, with TCM's efficacy heavily relying on syndrome differentiation [2] - Classic formulations with proven efficacy and a long history of use generally have lower risks and are easier to revise, while products with unclear sources and arbitrary formulations require more attention [2] Group 5: Broader Responsibilities - To ensure effective use of TCM, both companies and the medical sector must enhance their capabilities in syndrome differentiation and avoid empirical prescribing that deviates from syndrome-based treatment [3] - Public education is essential to improve understanding of TCM and promote safe medication practices, contributing to the orderly development of the TCM industry [3]

证券日报网讯 1月28日，康恩贝在互动平台回答投资者提问时表示，2024年，出口业务约占公司总收入 的8%，主要出口国为印度及中东国家。欧盟业务收入占公司整体收入比例较小，销售方式以直接向欧 盟客户出口和通过第三方贸易商、代理商转销两种方式为主。 （文章来源：证券日报） ...

（编辑 楚丽君） 证券日报网讯 1月28日，益盛药业在互动平台回答投资者提问时表示，公司管理层拥有丰富的行业经验 和企业管理经验，这是公司的宝贵财富。公司专注于人参行业的发展，持续优化内部管理，加大研发创 新和市场拓展力度，力争以更好的业绩回报广大投资者。 ...

Investment Rating - The report does not explicitly state an investment rating for the biopharmaceutical industry or Fitinib Core Insights - The report focuses on the market dynamics of Fitinib in China, including sales volume and revenue changes, as well as the impact of various factors such as market competition and healthcare policies [4][6][14] Summary by Sections Market Dynamics - In August 2025, the National Healthcare Security Administration released a preliminary review of the new medical insurance drug list, which included several innovative cancer drugs, raising concerns about changes in the healthcare payment structure [6] - The sales volume of Fitinib has shown significant fluctuations since 2025, influenced by market promotion, competition, and healthcare policies [7][9] - The sales volume for Fitinib in January 2025 was 15,265 boxes for the 1mg specification, which saw a decline of 22.0% in February, followed by a recovery in subsequent months [8][9] - The 5mg specification experienced more volatility, with sales dropping to a low of 4,015 boxes in March 2025 before rebounding [9] Sales Revenue - The sales revenue for Fitinib also exhibited notable fluctuations, with the 1mg specification reaching 3,863.0 million yuan in August 2025 after a decline in July [15][16] - The 5mg specification's revenue followed a similar pattern, indicating a competitive market landscape and the impact of healthcare policy adjustments on patient medication choices [16] - From August 2020 to August 2025, the sales revenue for the 1mg specification grew significantly in earlier years but saw a decline of 16.1% in August 2025, ending a five-year growth trend [21] Research and Development Progress - Fitinib has shown preliminary efficacy when combined with other treatments for locally advanced rectal cancer, with a complete resection rate of 100% among patients receiving the treatment [26][28] - The safety profile of Fitinib in combination therapies has been manageable, with most adverse events being of grade 1 or 2, indicating a favorable safety margin [27][28] - Ongoing studies are expected to provide further insights into the drug's efficacy and safety in various treatment regimens [28][32] Competitive Landscape - The report highlights the increasing competition in the pharmaceutical market, with multinational companies accelerating their investments and collaborations in China [6][22] - The emergence of new treatment modalities, such as antibody-targeted conjugates (ATTC), is reshaping the competitive landscape, offering potential advantages over traditional therapies [22]

Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range of 7.5 million to 11 million yuan, which represents a year-on-year decrease of 78.98% to 85.67% [1] Financial Performance - The projected basic earnings per share for 2025 are between 0.0307 yuan and 0.0451 yuan [1] - The decline in performance is attributed to a decrease in operating revenue compared to the previous year, influenced by market conditions and rising production costs due to increased raw material prices [1] Non-Recurring Gains - The impact of non-recurring gains on net profit is expected to decrease compared to the previous year, primarily due to the 2024 disposal of the "Salbutamol Granules" drug license and related production technology, which added approximately 16 million yuan to net profit [1] Strategic Response - The company plans to optimize its operational management and marketing strategies to enhance market development effectiveness [1] - It will utilize a strategy combining raw material price analysis and inventory adjustments to mitigate cost pressures from rising raw material prices [1] - The company aims to improve internal management efficiency to enhance operational management and profitability [1]

每经AI快讯，新天药业1月28日晚间发布公告称，公司第八届第四次董事会会议于2026年1月27日以通 讯表决的方式召开。会议审议了《关于对外转让药品上市许可及相关生产技术的议案》等文件。 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 （记者 王晓波） ...

Core Viewpoint - The controlling shareholder of Pian Zai Huang, Jiulongjiang Group, plans to increase its stake in the company by investing between 300 million and 500 million yuan from February 1 to July 31, marking the first increase since the company's listing [1] Group 1: Shareholder Actions - Jiulongjiang Group currently holds approximately 308 million shares of Pian Zai Huang, accounting for 50.97% of the total share capital [1] - The increase in shareholding is based on Jiulongjiang Group's confidence in the company's long-term investment value and sustainable development [1] Group 2: Stock Performance - Pian Zai Huang's stock price has been in a continuous decline, falling for nearly seven consecutive trading days, with a closing price of 156.10 yuan per share on January 28, resulting in a market capitalization of 94.18 billion yuan [1] - The stock has dropped over 20% in 2025, significantly underperforming the market [1] Group 3: Financial Performance - For the first three quarters of 2025, Pian Zai Huang reported revenue of 7.472 billion yuan, a year-on-year decrease of 11.93%, and a net profit of 2.129 billion yuan, down 20.74%, marking the first negative growth in nearly a decade [1] - The overall gross margin of the company is 38.9%, a decline of 6.5 percentage points year-on-year [1] Group 4: Market Conditions and Future Prospects - The decline in revenue growth and gross margin is attributed to the impact of the consumption environment and rising costs of natural cow bile [2] - However, the price of natural cow bile has shown signs of recovery, dropping from a peak of 1.65 million yuan per kilogram to 800,000 yuan per kilogram as of January 27 [2] - There are indications of a recovery in consumer demand, with online prices for core products showing a noticeable increase compared to the previous month [2] - Pian Zai Huang is also increasing its investment in pharmaceutical research and development, with its self-developed innovative drug PZH2113 capsule having completed the first subject enrollment in Phase I clinical trials [2]

证券日报网讯 1月28日，达仁堂发布公告称，公司于2026年1月28日以通讯方式召开了2026年第一次董 事会会议，会议审议通过了聘任陈洪先生为公司常务副总经理的议案。 （文章来源：证券日报） ...

Core Viewpoint - The company emphasizes the integration of artificial intelligence (AI) technology with the entire traditional Chinese medicine (TCM) industry chain, aiming for intelligent upgrades and high-quality development through AI applications in various core processes [1] Group 1: AI Integration in Operations - The company has developed the world's largest Ganoderma lucidum germplasm information database, utilizing digital breeding simulations and automated phenotype data collection for precise breeding, transitioning from experimental to data-driven biological breeding [1] - AI predictive models and image recognition technologies are employed to create smart farms, enabling precise control of the growth environment for medicinal materials and intelligent quality inspection [1] - The company has independently developed a customer service Q&A robot based on customized large models, establishing an AI dynamic knowledge engine to optimize operational processes and reduce labor costs [1] Group 2: Market and Consumer Insights - AI technology is used to analyze multi-channel data, constructing user profiles based on age, physical condition, and consumption preferences, which aids in precise advertising and personalized product recommendations [1] - The company plans to continue deepening the integration of "AI + TCM" innovation, further promoting intelligent upgrades across the entire industry chain [1]

Group 1 - Yunnan Province ranks first globally in the production of tin, indium, and germanium, and has the most complete platinum group metals and titanium industry chain in China [2][3] - The province is recognized as a major agricultural hub in China, with significant achievements in highland characteristic agriculture, including the highest global production of flowers and the largest number of organic product certifications in China [2][3] - Yunnan is a leader in ecological civilization, achieving the highest ranking in China for the assessment of civilized, healthy, and environmentally friendly lifestyles for two consecutive years, and aims for a 98.9% rate of good air quality days by 2025 [3] Group 2 - Yunnan Baiyao has been recognized as the world's first "Lighthouse Factory" in the field of traditional Chinese medicine health products, showcasing the highest level of intelligent manufacturing and digitalization [4] - The province has established a new advantage in "green electricity + advanced manufacturing," with major hydropower projects like the Wudongde and Baihetan power stations contributing to a total installed capacity exceeding 170 million kilowatts, ranking high in green electricity capacity and proportion in China [4]